InvestorWaves

Digital Health & Care Delivery

Digital Health & Care Delivery covers companies that move diagnosis, treatment, administration, and payment out of traditional hospitals and into software, home settings, outpatient clinics, and insurer-aligned networks. Capital flows to firms that use software, remote monitoring, and new care models to lower costs, improve access, and align incentives across payors, providers, and patients.

1D+0.5%
1W+0.5%
1M-3.0%
3M+2.6%
6M+37.5%
1Y+21.7%

9 of 16 stocks are in a Stage 2 uptrend.

Equal-weighted index · 1 year+21.7%
80100120OCTJANAPRJUL

Stocks in this theme

TickerPrice1M3M1YStageTrendvs 52w high
HTFLHeartflow, Inc.$49.75-1.3%+62.0%+44.2%Stage 2 (extended)7/7-1.97%
AVAHAveanna Healthcare Holdings, Inc.$12.41-7.5%+40.1%+39.9%Stage 2 (extended)7/7-13.7%
DOCSDoximity, Inc.$28.34+6.1%+31.3%-62.3%Stage 13/7-61.46%
WAYWaystar Holding Corp.$25.34-3.4%+23.4%-31.7%Stage 13/7-36.04%
CRVLCorvel Corp$74.55+8.2%+15.6%-3.5%Stage 15/7-3.87%
HNGEHinge Health, Inc.$97.24+5.1%+14.3%+94.9%Stage 2 (extended)7/70%
CONConcentra Group Holdings Parent, Inc.$34.42+2.0%+11.9%+65.8%Stage 2 (continuation)7/7-5.36%
RMDResmed Inc$221.1-7.9%+9.9%-18.4%Stage 32/7-21.95%
OPCHOption Care Health, Inc.$22.49-4.1%+6.9%-18.3%Stage 40/7-38.54%
LFSTLifeStance Health Group, Inc.$12.03-2.7%+5.3%+128.7%Stage 2 (continuation)7/7-10.09%
GRDNGuardian Pharmacy Services, Inc.$40.78+9.9%-3.2%+56.4%Stage 2 (re-acceleration)7/7-15.04%
OSCROscar Health, Inc.$30.84+2.9%-3.3%+67.4%Stage 2 (continuation)7/7-8.78%
BTSGBrightSpring Health Services, Inc.$56.75-2.8%-18.8%+101.7%Stage 2 (re-acceleration)7/7-22.16%
PRVAPrivia Health Group, Inc.$19.69-3.9%-26.8%-17.8%Stage 10/7-29.93%
EVHEvolent Health, Inc.$3.49-24.1%-35.6%-61.0%Stage 13/7-60.21%
ALHCAlignment Healthcare, Inc.$8.16-39.1%-66.0%-52.9%Stage 40/7-66.78%

Deep dive

The theme groups firms that combine clinical services, software platforms, and medical devices to change how care is delivered and paid for. Examples include home- and community-based care operators that deliver nursing and therapy in patients' homes, digital-first providers that offer virtual visits and behavioral or musculoskeletal programs, clinical diagnostics and device makers that enable remote monitoring, and payer-oriented companies that manage benefits, billing, and value-based contracts.

Demand for these services comes from several concrete forces. Aging populations and rising chronic disease increase long-term care needs while workforce shortages make in-person institutional care more expensive. Payers and large employers push toward value-based reimbursement to control costs, and consumers expect more convenient, digital-first access to clinicians. Advances in telehealth platforms, cloud data, and edge devices make remote care and continuous monitoring technically feasible, which attracts investment into scaled software and recurring-revenue business models.

The value chain splits into distinct roles. Device and durable-goods makers produce hardware and remote sensors and integrate those signals into clinical workflows. Software and platform companies provide telehealth, care-coordination, billing, and claims automation. Clinical operators deliver hands-on services at home or in outpatient clinics and manage care pathways under fee-for-service or value-based contracts. Payor-facing firms package networks, manage risk, and broker payment arrangements, while specialty pharmacies and infusion providers handle complex medication delivery and outpatient therapeutics.

Whether the theme continues to attract capital depends on measurable outcomes and economic incentives. Payers and employers require evidence that digital care and outside-hospital services reduce total cost of care without worsening outcomes, and reimbursement rules must support remote services and value-based contracts. Integration with electronic health records, data security, and reliable clinical workflows affect adoption by clinicians. Profitability at scale, patient engagement and retention, and regulatory policy on Medicare, Medicaid, and commercial reimbursement also determine long-term viability.

Other themes